Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining optical genome mapping (OGM) with targeted next-generation sequencing (NGS) to improve the diagnosis and prognostication of myelodysplastic syndromes (MDS). Dr Kanagal-Shamanna explains that these technologies are highly accurate, can uncover novel targetable mutations, and can overcome the challenges experienced with currently used methods to characterize the genomics of MDS. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть